Skip to main content

Table 1 Demographic, baseline clinical, and medications among the two groups

From: Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure

 

Carvedilol group (N = 25)

Nebivolol group (N = 18)

P value

Age

50.5 ± 10.5

50.9 ± 9.6

0.89

Wt (kg )

83.3 ± 12

81.4 ± 10

0.58

BMI(kg/m2)

37.0 ± 6.1

36.8 ± 4.3

0.9

Waist circum(cm )

118.6 ± 10.5

117.3 ± 9.9

0.68

Male gender

14 (56%)

10 (55.6%)

o.8

Smokers

8 (33%)

4 (22.2%)

0.48

TG (mg/dl)

132 ± 4.5

134 ± 3.5

0.12

HDL(mg/dl)

38 ± 6.2

39 ± 5.3

0.59

Uric acid(mg/dl)

8.1 ± 2.6

8.0 ± 2.3

0.89

Hb% (gm)

13.5 ± 1.2

13.0 ± 2.1

0.36

Medications

   

 Loop diuretic

17 (68%)

12 (66.7%)

0.93

 Aldosterone blocker

15 (60%)

5 (27.8%)

0.036*

 RAS blocker

23 (92%)

17 (94.4%)

0.99

 Digoxin

6 (24%)

4 (22.2%)

0.99

 ASA

19 (76%)

14 (77.8%)

0.99

  1. ASA aspirin, BMI body mass index, HB hemoglobin, HDL high-density lipoprotein, RAS renin-angiotensin-system, TG triglyceride
  2. *P is significant